Investment Q&A

Q: Do you have an estimate of SIS earnings per share for say 2019 with their Swiss acquisition and any observations on issues associated with the integration of the new co; also is your price target of 21 based on the combined earnings and for which year?

Thanks

Q: What is the short interest on Reliq?

Q: I bought RHT at about 1.85 and didn't follow my own rule about limiting downside. With it sitting where it is now should it be kept or replaced? Could you name 3 growth oriented names (in portfolio or otherwise that you would rather hold if selling RHT?

Q: Thoughts on the RBC analyst posting an $11 target? Quite a drop on that. Would you buy on this dip? What price target would you put on the stock in a buyout scenario by a larger company? Is this likely?

Q: SIS has a surprised 5% pop today against a sea of red. Are you aware of any upcoming news? Usually (of course I'm just guessing here) that is a sign of a potential buyout, but I could be reading too much into this unusual one day move. Please enlighten me. Thanks.

Q: Hi, would you have any problems buying more cov to a full position at under $10, or would you wait for it to settle back a bit from it’s big move?
Thanks

Q: Hello 5I Team.
I'm intrigued with the heavy insider purchasing in Acerus Pharm, and, I like the business they are in. I took a very small position but would really appreciate your analysis prior to adding to ASP.
Thank you!
Brian

Q: Hello 5i!!!
Could I have your thoughts on Tandem Diabetes Care ?
Anything else in the sector you might prefer for a higher risk investor?
Thank you
Dave

Q: All things being neutral, what would your expectations be for Covalon's 2018 and 2019 earnings per share? Also, can you give a brief history of their cash levels (maybe for the previous 3 or 4 quarters?)

Secondly, I know you are not fans of averaging down. However, if you WERE to average down, would you take your initial purchase price in trying to determine your percentage weighting, or would you take the current market price? Example, lets say I take a 2% position in Covalon, which theoretically I would want to be my maximum weighting. Shortly afterwards the share price falls 50% (for the sake of easy math). Would I prohibit myself in buying more Covalon because my initial purchase price represented 2% of my portfolio or would I grant myself the option of averaging down because now my weighting in Covalon represents 1% of my portfolio, assuming my portfolio value remained the same.

Thanks and good luck to the staff's kids for their new school year.

John

Q: You say insiders have been buying reliq, where do you see that, i see no sigh of that. thanks

Q: Hi,
PLI has been moving up quickly the last couple of days...is there any news as to why it is moving up? Are you still predicting headwinds for this company?
Thanks

Q: Hi, I got in at a really good price and rode this to the $2.00 mark and sold most of my shares.
Do you think its a good investment at the current mid$1.40s or do you think it might go down a bit more? The charts seem to indicate its heading down.
Thanks !!

Q: Good morning Could you give me your thoughts on this company thanks Norm

Q: TH is om the move UP. What kind of upside do you see here.? What do insiders own ? RAK

Q: Further comment about press releases sent directly to investors from Covalon CEO Jeffrey Mandel: I own that stock. If memory serves, the stock hit a high of 9.15 on August 6 and then appears (in my naive understanding) to have become the victim of a short attack. Trading was halted and IIROC then asked the CEO what material change(s) -- if any -- might account for the abrupt drop -- which hit a low of 6.26 (nearly 40%). As an investor, I took Mandel's first direct emails (which began at that time) as reassurance to investors not to panic and dump the stock. COV has recovered somewhat since then, but I'm assuming that Mandel might be sensitive to the potential of another assault against his company (e.g., SHOP) and may want to inform investors directly of positive progress being made -- which include the last couple of messages that just arrived in my inbox.

Q: Since buying COV, I've started receiving regular emails such as these 2 yesterday:
"Covalon Announces Another Milestone Quarterly Profit on Excellent Third Quarter Financial Results"

"Covalon's excellent earnings listed on Globe and Mail small cap movers list"

I have never received these types of emails on this regular of a basis from other companies that I own. Should I be concerned about the promotional nature here?

Q: Hi Team

In Healthcare I own SYK GUD and COV. I would like to buy another US Health. Which of ILMN or ISRG would you recommend today. I have read all your recommendations but just cant decide...looking for the most growth of course. Dividends do not matter.

Thank you

Q: Can you comment on the recent earnings? Is here any hope for this stock?

Q: Please comment on earnings. Thanks

Q: Covalon has spent just over $700K on R&D for the six months recently reported according to my reading of the financials. This is a small number for a company looking to grow significantly. How can they develop new products with such a low ongoing investment? How do you see this?